1. Home
  2. PROK vs CMCM Comparison

PROK vs CMCM Comparison

Compare PROK & CMCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PROK
  • CMCM
  • Stock Information
  • Founded
  • PROK 2015
  • CMCM 2009
  • Country
  • PROK United States
  • CMCM China
  • Employees
  • PROK N/A
  • CMCM N/A
  • Industry
  • PROK Biotechnology: Biological Products (No Diagnostic Substances)
  • CMCM Computer Software: Prepackaged Software
  • Sector
  • PROK Health Care
  • CMCM Technology
  • Exchange
  • PROK Nasdaq
  • CMCM Nasdaq
  • Market Cap
  • PROK 126.8M
  • CMCM 127.6M
  • IPO Year
  • PROK N/A
  • CMCM 2014
  • Fundamental
  • Price
  • PROK $1.02
  • CMCM $3.93
  • Analyst Decision
  • PROK Buy
  • CMCM
  • Analyst Count
  • PROK 4
  • CMCM 0
  • Target Price
  • PROK $5.00
  • CMCM N/A
  • AVG Volume (30 Days)
  • PROK 1.3M
  • CMCM 35.2K
  • Earning Date
  • PROK 05-09-2025
  • CMCM 06-06-2025
  • Dividend Yield
  • PROK N/A
  • CMCM N/A
  • EPS Growth
  • PROK N/A
  • CMCM N/A
  • EPS
  • PROK N/A
  • CMCM N/A
  • Revenue
  • PROK $76,000.00
  • CMCM $110,544,725.00
  • Revenue This Year
  • PROK N/A
  • CMCM $14.27
  • Revenue Next Year
  • PROK N/A
  • CMCM $39.26
  • P/E Ratio
  • PROK N/A
  • CMCM N/A
  • Revenue Growth
  • PROK N/A
  • CMCM 20.52
  • 52 Week Low
  • PROK $0.46
  • CMCM $3.02
  • 52 Week High
  • PROK $4.44
  • CMCM $6.78
  • Technical
  • Relative Strength Index (RSI)
  • PROK 60.91
  • CMCM 46.40
  • Support Level
  • PROK $0.66
  • CMCM $3.81
  • Resistance Level
  • PROK $0.89
  • CMCM $4.00
  • Average True Range (ATR)
  • PROK 0.17
  • CMCM 0.23
  • MACD
  • PROK 0.06
  • CMCM 0.08
  • Stochastic Oscillator
  • PROK 77.78
  • CMCM 97.22

About PROK ProKidney Corp.

ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's own cells isolated from the patient intended for treatment. Its lead product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's own renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of development program for severe diabetic kidney disease.

About CMCM Cheetah Mobile Inc. each representing fifty (50)

Cheetah Mobile Inc along with its subsidiaries provides comprehensive products and services on PCs and mobile devices. It generates revenue from utility-related business, including advertising services and premium membership services. It also provides multi-cloud management platform and overseas advertising agency service. The company operates in two segments: Internet business, and AI and others. The firm's majority of the revenue is derived from the internet business segment that provides mobile advertising services to advertising customers, as well as selling advertisements and referring user traffic on its mobile and PC platforms. Geographically, it derives the majority of its revenue from the PRC and the rest from Hong Kong, Japan, and the rest of the world.

Share on Social Networks: